<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20813" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tardive Dystonia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fariba</surname>
            <given-names>Kamron A.</given-names>
          </name>
          <aff>University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Estevez</surname>
            <given-names>Ryan</given-names>
          </name>
          <aff>University of South Florida and (unaffiliated) Tampa Bay Neurobehavior Institute</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kamron Fariba declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ryan Estevez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20813.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Tardive dystonia (TD) is one of the extrapyramidal syndromes caused by the use of dopaminergic receptor antagonists. If not recognized promptly and appropriately managed, symptoms can worsen or remain indefinitely. This activity outlines the evaluation and management of tardive dystonia and highlights the role of the interprofessional team in providing care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of tardive dystonia.</p></list-item><list-item><p>Review the appropriate evaluation of tardive dystonia.</p></list-item><list-item><p>Outline the most appropriate management options available for tardive dystonia.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance the care of tardive dystonia and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20813&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20813">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20813.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Extrapyramidal symptoms (EPS) were first witnessed in the 1950s following the discovery of the then-novel class of medication known as neuroleptics.<xref ref-type="bibr" rid="article-20813.r1">[1]</xref>&#x000a0;Manifestations of EPS were first officially reported at the &#x0201c;Swiss Symposium on Chlorpromazine&#x0201d; in 1953.<xref ref-type="bibr" rid="article-20813.r2">[2]</xref>&#x000a0;The therapeutic efficacy of this&#x000a0;new drug class, in parallel with its extrapyramidal activity, resulted in the designation of the term &#x0201c;neuroleptic,&#x0201d; as these drugs were primarily thought to aid in calming psychomotor agitation.<xref ref-type="bibr" rid="article-20813.r3">[3]</xref>&#x000a0;It was initially thought EPS manifested promptly after neuroleptic administration. However, subsequent latent motor abnormalities would challenge these assumptions.</p>
        <p>In 1957, Schoenecker submitted the first report of what would later be identified as &#x0201c;tardive dyskinesia&#x0201d; as he described the bucco-oral movements of a patient on chronic neuroleptic therapy. It was he who articulated the distinction between this latent phenomenology and acute extrapyramidal side effects.<xref ref-type="bibr" rid="article-20813.r2">[2]</xref>&#x000a0;In 1964, the term &#x0201c;tardive dyskinesia&#x0201d; was officially implemented into the psychiatric vernacular, by Faurbye. In 1973, Keegan and Rajputa offered &#x0201c;dystonia tarda&#x0201d; to the psychiatric nosology, following the account of a female patient with latent torticollis.<xref ref-type="bibr" rid="article-20813.r4">[4]</xref> This initial report was, in turn, followed by a comprehensive description in 1982, formally identifying the phenomenon known as &#x0201c;tardive dystonia.&#x0201d;<xref ref-type="bibr" rid="article-20813.r4">[4]</xref> Dystonias are defined as involuntary movement disorders that are distressing and often painful. They are characterized by twisting and repetitive postures resulting from transient or intermittent spasms of antagonistic muscle groups.<xref ref-type="bibr" rid="article-20813.r5">[5]</xref></p>
      </sec>
      <sec id="article-20813.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The precise pathophysiological mechanism of tardive dystonia is unknown.<xref ref-type="bibr" rid="article-20813.r6">[6]</xref>&#x000a0;It is generally accepted that dopaminergic antagonism leads to excessive compensatory activity, resulting in dystonia as the inciting drug is metabolized and diluted.&#x000a0;Some postulate that dystonia is simply the result of excessive dopamine blockade.<xref ref-type="bibr" rid="article-20813.r3">[3]</xref>&#x000a0;Either mechanism includes the involvement of the nigrostriatal tract. It is believed that&#x000a0;aberrant&#x000a0;dopaminergic activity within the basal ganglia, subsequently leads to extrapyramidal symptoms. The&#x000a0;medications that cause this dopamine receptor blocking are neuroleptics. Apart from these antipsychotics, other dopamine antagonists have also been implicated.<xref ref-type="bibr" rid="article-20813.r3">[3]</xref></p>
      </sec>
      <sec id="article-20813.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Acute and tardive dystonic reactions occur less frequently than other&#x000a0;related EPS manifestations, such as Parkinson's-like symptoms and akathisia. There is some debate regarding the chances of developing tardive dystonia, with studies suggesting it is somewhere between &#x0003c;1 to 2%&#x000a0; of patients taking antipsychotics.<xref ref-type="bibr" rid="article-20813.r7">[7]</xref> Risk factors include age, males, previous history of dystonic reactions, cocaine use, electrolyte abnormalities, and dehydration.<xref ref-type="bibr" rid="article-20813.r8">[8]</xref> Consistent across most studies is the predominance of young males developing tardive dystonia more frequently. It is possible this sex difference is merely a reflection of the earlier age of onset of schizophrenia in males.<xref ref-type="bibr" rid="article-20813.r4">[4]</xref>&#x000a0;</p>
        <p>One study revealed the interval between the age at first exposure to the neuroleptic and the age at onset of tardive dystonia ranged from four days to twenty-three years, with a mean of about six years. In this same study, researchers noted that younger patients experienced a shorter interval from neuroleptic exposure to symptom presentation.<xref ref-type="bibr" rid="article-20813.r4">[4]</xref>&#x000a0;Similarly, those who experienced the onset of dystonia at a younger age experienced more rapid symptom progression.</p>
      </sec>
      <sec id="article-20813.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Tardive dystonia often has an insidious and progressive presentation. Although associated with a latent and thus &#x0201c;tardive&#x0201d; onset, the presentation may occur anywhere from days to years following initial exposure to dopamine receptor antagonism. Patients have reported that unusual sensory symptoms, along with strange somatic sensations, have preceded the onset of tardive dystonia. For example, neck pain has been found to&#x000a0;precede the onset of cervical dystonia. Furthermore, research has determined that the development of tardive manifestations presents as focal dystonia, most notably torticollis or blepharospasm, followed by pharyngeal dystonia, oromandibular dystonia, and dystonia of the lips and tongue.</p>
        <p>Dystonias of the arms, legs, and trunk are less frequent. On examination, pharyngeal dystonia will present as dysphagia, whereas oromandibular dystonia may present as a severe speech disturbance.<xref ref-type="bibr" rid="article-20813.r4">[4]</xref>&#x000a0;Tardive dystonia will less often occur focally and instead tends to distribute more diffusely.</p>
      </sec>
      <sec id="article-20813.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Prompt recognition&#x000a0;and subsequent intervention are paramount in the setting of tardive dystonia. Proper evaluation&#x000a0;begins with reviewing the primary diagnosis, describing the precipitating motor abnormalities, assessing symptom severity, and finally, by developing a treatment plan based upon the specific phenomenology. It is important that the clinician review the full medical profile, as alternative dopaminergic antagonizing&#x000a0;medications have been known to induce tardive syndromes. Such inciting agents include dopamine receptor blocking anti-emetics, including prochlorperazine, metoclopramide, and promethazine.<xref ref-type="bibr" rid="article-20813.r9">[9]</xref></p>
      </sec>
      <sec id="article-20813.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Upon the proper identification of tardive dystonia, the&#x000a0;offending agent(s) should be modified and if possible, discontinued. Clinical judgment will indicate whether abrupt cessation or a gradual taper is most appropriate.&#x000a0;Some experts suggest simply cross-tapering to an alternative antipsychotic with a lower EPS profile, such as clozapine.</p>
        <p>Drug-induced EPS are believed to precipitate following the blockade of nigrostriatal dopamine tracts, ultimately resulting in an increased ratio of cholinergic to dopaminergic activity. Therefore, drugs that antagonize cholinergic activity and increase striatal dopaminergic function will theoretically normalize the biochemical imbalance.<xref ref-type="bibr" rid="article-20813.r10">[10]</xref></p>
        <p>One study reviewed the therapeutic efficacy of specific pharmacologic interventions and revealed &#x0201c;at least some benefit&#x0201d; in 53% of patients&#x000a0;following the&#x000a0;administration of tetrabenazine, 44% with anticholinergic agents, 56% with benzodiazepines, and 56% with baclofen.<xref ref-type="bibr" rid="article-20813.r4">[4]</xref>&#x000a0;The most robust therapeutic effects were experienced&#x000a0;following botulin toxin&#x000a0;administration, where 83% of patients&#x000a0;endorsed &#x0201c;considerable relief.&#x0201d;<xref ref-type="bibr" rid="article-20813.r4">[4]</xref>&#x000a0;Other therapeutic agents to consider include L-dopa, dopamine agonists, amantadine, beta-blockers, anticonvulsants, choline, and vitamin E.</p>
      </sec>
      <sec id="article-20813.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The list of differential diagnoses for tardive dystonia is extensive and includes primary and secondary etiologies of dystonias. Secondary forms of dystonia include metabolic abnormalities, toxic states, neurodegenerative disorders, and structural abnormalities of the brain.<xref ref-type="bibr" rid="article-20813.r11">[11]</xref></p>
        <p>Drug-induced dystonic syndromes can be distinguished by acknowledging a history of neuroleptic treatment, negative family history of primary dystonia, and the absence of associated neurological signs. It is not uncommon for patients on chronic neuroleptics to present with tardive syndromes. Furthermore, patients can experience more than one of these tardive syndromes simultaneously, further complicating matters. These latent motor abnormalities can be further subdivided into three major subtypes, including tardive dyskinesia, tardive dystonia, and tardive akathisia.</p>
        <p>Tardive dyskinesia is characterized by truncal, appendicular, or orobuccolingual choreiform movements; whereas tardive dystonia manifests as stereotyped twisting and turning muscle spasms. Tardive dyskinesia also tends to have a&#x000a0;later age of onset than tardive dystonia.<xref ref-type="bibr" rid="article-20813.r4">[4]</xref> One study found the mean age of onset of tardive dyskinesia in a research group to be 57 years old and that of tardive dystonia to be 37 years old.<xref ref-type="bibr" rid="article-20813.r9">[9]</xref>&#x000a0;Tardive akathisia shares less in common with its two sister tardive syndromes and is defined as an unpleasant inner sense of restlessness or unease, ultimately indistinguishable from acute akathisia.</p>
      </sec>
      <sec id="article-20813.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Once established, the progression of the dystonia tends to evolve in a stepwise fashion over months to years, with subsequent involvement of additional body parts. Studies reveal that progression to maximum intensity and distribution occurs within 2 years from onset. More rapid progression has been noted in the population with a younger age at onset.<xref ref-type="bibr" rid="article-20813.r4">[4]</xref> Tardive syndromes can be a source of intense distress and potential disability. Unfortunately, these syndromes can be permanent, even after the discontinuation of the offending agent.<xref ref-type="bibr" rid="article-20813.r9">[9]</xref>&#x000a0;</p>
        <p>One study&#x000a0;attempted&#x000a0;to demarcate outcome groups based upon symptom resolution following treatment. In this study of 107 patients being treated for tardive dystonia, 14% were in remission, 39% were improved, and 50% noted either no improvement or&#x000a0;exacerbating symptomatology.<xref ref-type="bibr" rid="article-20813.r4">[4]</xref>&#x000a0;Within this cohort, those who discontinued their neuroleptic were more likely to have experienced symptom remission. More specifically, those who discontinued antipsychotics more rapidly benefitted from a higher likelihood of remission.<xref ref-type="bibr" rid="article-20813.r4">[4]</xref> Remission was reached within a mean of 2.4 years from the discontinuation of all neuroleptic agents.<xref ref-type="bibr" rid="article-20813.r4">[4]</xref>&#x000a0;Furthermore, dystonia appears irreversible in those exposed to neuroleptics for greater than 10 years.</p>
      </sec>
      <sec id="article-20813.s10" sec-type="Complications">
        <title>Complications</title>
        <p>The severity of tardive dystonia ranges on a spectrum from imperceptible to frank disability. Subtle impairments include muscle tightness and cramps, leading to mastication and speech discomfort. More intense complications include oculogyric crisis, dysphagia, dysarthria, as well as lethal respiratory stridor. In severe instances, dystonic reactions can induce apnea, leading to fatality. Less common complications include dystonic involvement of axial, limb, and truncal muscle groups leading to Pisa syndrome, camptocormia, and opisthotonus.<xref ref-type="bibr" rid="article-20813.r3">[3]</xref></p>
      </sec>
      <sec id="article-20813.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Prognosis improves when EPS symptoms are detected promptly.<xref ref-type="bibr" rid="article-20813.r9">[9]</xref>&#x000a0;Moreover, lower doses of neuroleptics have been associated with a decreased incidence of dystonia, as well as antipsychotics with minimal dopamine antagonism.<xref ref-type="bibr" rid="article-20813.r12">[12]</xref> This association has been the foundational impetus for the development of novel agents with less dopamine antagonism. Because of their reduced activity at the dopamine receptor, atypical antipsychotics tend to be preferred over high potency first-generation antipsychotics.<xref ref-type="bibr" rid="article-20813.r13">[13]</xref> One study found that haloperidol had a four-fold greater risk of inducing dystonic manifestations than atypical antipsychotics.<xref ref-type="bibr" rid="article-20813.r14">[14]</xref><xref ref-type="bibr" rid="article-20813.r15">[15]</xref><xref ref-type="bibr" rid="article-20813.r16">[16]</xref> Some clinicians prefer to administer prophylactic anticholinergic agents when prescribing neuroleptics to obviate potential EPS.<xref ref-type="bibr" rid="article-20813.r17">[17]</xref></p>
      </sec>
      <sec id="article-20813.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Tardive dystonia can be debilitating and possibly even life-threatening. It is critical that the interprofessional team be knowledgeable and up to date regarding the possible precipitation of tardive dystonia. All members of the team must remain vigilant in the event&#x000a0;the patient begins to experience prodromal symptomatology, as research suggests more rapid&#x000a0;intervention results in&#x000a0;better patient outcomes.<xref ref-type="bibr" rid="article-20813.r9">[9]</xref>&#x000a0;In the inpatient setting, nurses and staff members will most likely have the most contact with patients, and therefore if they observe concerning manifestations, they should promptly notify the clinician. Teamwork and proactive management will result in the best possible patient care.</p>
      </sec>
      <sec id="article-20813.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20813&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20813">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/tardive-dystonia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20813">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20813/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20813">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20813.s14">
        <title>References</title>
        <ref id="article-20813.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waln</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Jankovic</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>An update on tardive dyskinesia: from phenomenology to treatment.</article-title>
            <source>Tremor Other Hyperkinet Mov (N Y)</source>
            <year>2013</year>
            <volume>3</volume>
            <pub-id pub-id-type="pmid">23858394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20813.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolf</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Yassa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Llorca</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>[Neuroleptic-induced movement disorders: historical perspectives].</article-title>
            <source>Encephale</source>
            <year>1993</year>
            <season>Nov-Dec</season>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>657</fpage>
            <page-range>657-61</page-range>
            <pub-id pub-id-type="pmid">12404786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20813.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caroff</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Hurford</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lybrand</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.</article-title>
            <source>Neurol Clin</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>127</fpage>
            <page-range>127-48, viii</page-range>
            <pub-id pub-id-type="pmid">21172575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20813.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiriakakis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Marsden</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>The natural history of tardive dystonia. A long-term follow-up study of 107 cases.</article-title>
            <source>Brain</source>
            <year>1998</year>
            <month>Nov</month>
            <volume>121 ( Pt 11)</volume>
            <fpage>2053</fpage>
            <page-range>2053-66</page-range>
            <pub-id pub-id-type="pmid">9827766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20813.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rupniak</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Jenner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marsden</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Acute dystonia induced by neuroleptic drugs.</article-title>
            <source>Psychopharmacology (Berl)</source>
            <year>1986</year>
            <volume>88</volume>
            <issue>4</issue>
            <fpage>403</fpage>
            <page-range>403-19</page-range>
            <pub-id pub-id-type="pmid">2871578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20813.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berardelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rothwell</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hallett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Manfredi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marsden</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>The pathophysiology of primary dystonia.</article-title>
            <source>Brain</source>
            <year>1998</year>
            <month>Jul</month>
            <volume>121 ( Pt 7)</volume>
            <fpage>1195</fpage>
            <page-range>1195-212</page-range>
            <pub-id pub-id-type="pmid">9679773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20813.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Harten</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Hoek</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Acute dystonia induced by drug treatment.</article-title>
            <source>BMJ</source>
            <year>1999</year>
            <month>Sep</month>
            <day>04</day>
            <volume>319</volume>
            <issue>7210</issue>
            <fpage>623</fpage>
            <page-range>623-6</page-range>
            <pub-id pub-id-type="pmid">10473482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20813.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keepers</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Prediction of neuroleptic-induced dystonia.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>1987</year>
            <month>Oct</month>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>342</fpage>
            <page-range>342-5</page-range>
            <pub-id pub-id-type="pmid">2890672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20813.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skidmore</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Tardive Dystonia.</article-title>
            <source>Curr Treat Options Neurol</source>
            <year>2005</year>
            <month>May</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>231</fpage>
            <page-range>231-236</page-range>
            <pub-id pub-id-type="pmid">15814076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20813.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glazer</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2000</year>
            <volume>61 Suppl 3</volume>
            <fpage>16</fpage>
            <page-range>16-21</page-range>
            <pub-id pub-id-type="pmid">10724129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20813.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>N&#x000e9;meth</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>The genetics of primary dystonias and related disorders.</article-title>
            <source>Brain</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>125</volume>
            <issue>Pt 4</issue>
            <fpage>695</fpage>
            <page-range>695-721</page-range>
            <pub-id pub-id-type="pmid">11912106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20813.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keepers</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Clappison</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes.</article-title>
            <source>Arch Gen Psychiatry</source>
            <year>1983</year>
            <month>Oct</month>
            <volume>40</volume>
            <issue>10</issue>
            <fpage>1113</fpage>
            <page-range>1113-7</page-range>
            <pub-id pub-id-type="pmid">6138011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20813.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caroff</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Movement disorders associated with atypical antipsychotic drugs.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2002</year>
            <volume>63 Suppl 4</volume>
            <fpage>12</fpage>
            <page-range>12-9</page-range>
            <pub-id pub-id-type="pmid">11913670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20813.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arvanitis</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.</article-title>
            <source>Biol Psychiatry</source>
            <year>1997</year>
            <month>Aug</month>
            <day>15</day>
            <volume>42</volume>
            <issue>4</issue>
            <fpage>233</fpage>
            <page-range>233-46</page-range>
            <pub-id pub-id-type="pmid">9270900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20813.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tollefson</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Beasley</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Street</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Krueger</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Graffeo</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Thieme</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.</article-title>
            <source>Am J Psychiatry</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>154</volume>
            <issue>4</issue>
            <fpage>457</fpage>
            <page-range>457-65</page-range>
            <pub-id pub-id-type="pmid">9090331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20813.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simpson</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Lindenmayer</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Extrapyramidal symptoms in patients treated with risperidone.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>194</fpage>
            <page-range>194-201</page-range>
            <pub-id pub-id-type="pmid">9169965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20813.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arana</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Goff</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Baldessarini</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Keepers</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia.</article-title>
            <source>Am J Psychiatry</source>
            <year>1988</year>
            <month>Aug</month>
            <volume>145</volume>
            <issue>8</issue>
            <fpage>993</fpage>
            <page-range>993-6</page-range>
            <pub-id pub-id-type="pmid">2899403</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
